Objective: We conducted a longitudinal prospective study to evaluate the long-term effect of pregnancy on the progression of multiple sclerosis (MS). Method: Parous female MS patients were extracted from the database of Isfahan Multiple Sclerosis Society (IMSS). Through comparing the annual relapsing rate during a mean of 4 years before pregnancy versus a mean of 6 years after delivery, MS progression influenced by the pregnancy was analyzed. Result: 102 female patients were included in our study. The mean annual relapsing rate 4 years prior to pregnancy was significantly higher than at the subsequent 6 years after delivery (1.06 vs. 0.45, p < 0.001). In addition, the annual relapsing rate in years prior to pregnancy was significantly higher than each trimester of gestation (p < 0.001). Furthermore, there was a 2.2-fold increased risk of having a relapse in individuals who had experienced more relapses prior to pregnancy, and a 0.8-fold decreased in the risk of having more relapses with older age at the onset of MS. Conclusion: Although the course of MS was deteriorated 3 months after delivery, it was not statistically significant comparing annual relapsing rates during the years prior to pregnancy. Moreover, the rate of disease progression slowed down in the 6-year period monitored after delivery.

1.
Birk K, Ford C, Smeltzer S, Ryan D, Miller R, Rudick RA: The clinical course of multiple sclerosis during pregnancy and the puerperium. Arch Neurol 1990;47:738–742.
2.
Duquette P, Pleines J, Girard M, Charest L, Senecal Quevillon M, Masse C: The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992;19:466–471.
3.
Confavreux C, Aimard G, Devic M: Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281–300.
4.
Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers G: The natural history of multiple sclerosis: a geographically based study. III. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045–1056.
5.
Confavreux C, Vukusic S, Adeleine P: Early predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770–782.
6.
Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick D, Ebers GC, Canadian Collaborative Study Group: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5:932–936.
7.
Douglass LH, Jorgensen CL: Pregnancy and multiple sclerosis. Am J Obstet Gynecol 1948;55:332–336.
8.
Sweeney WJ: Pregnancy and multiple sclerosis. Am J Obstet Gynecol 1953;66:124–130.
9.
Tillman AJB: The effect of pregnancy on multiple sclerosis and its management. Res Publ Assoc Res Nerv Ment Dis 1950;28:546–582.
10.
Rudick RA: Pregnancy and multiple sclerosis. Arch Neurol 1995;52:849–850.
11.
Confavreux C, Hutchinson M, Hours M, Cortinovis-Tourniaire P, Moreau T: Rate of pregnancy related relapse in multiple sclerosis. N Engl J Med 1998;339:285–291.
12.
Saadatnia M, Etemadifar M, Maghzi AH: Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol 2007;79:357–375.
13.
Etemadifar M, Maghzi AH: Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Multiple Scler J 2011;17:1022–1027.
14.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005;58:8406.
15.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
16.
Houtchens MK: Pregnancy and multiple sclerosis. Semin Neurol 2007;27:434–441.
17.
Saraste M, Väisänen S, Alanen A, Airas L, Finnish Multiple Sclerosis and Pregnancy Study Group: Clinical and immunologic evaluation of women with multiple sclerosis during and after pregnancy. Gend Med 2007;4:45–55.
18.
Salemi G, Callari G, Gammino M, Battaglieri F, Cammarata E, Cuccia G, D’Amelio M, Lupo I, Ragonese P, Savettieri G: The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand 2004;110:23–26.
19.
Frith JA, McLeod JG: Pregnancy and multiple sclerosis. J Neurol Neurosurg Psychiatry 1988;51:495–498.
20.
Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C, Pregnancy in Multiple Sclerosis Group: Pregnancy and multiple sclerosis (the Prims study): clinical predictors of post-partum relapse. Brain 2004;127:1353–1360.
21.
Sim FJ, Zhao C, Penderis J, Franklin RJ: The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002;22:2451–2459.
22.
Confavreux C, Vukusic S: Age at disability milestones in multiple sclerosis. Brain 2006;129:595–605.
23.
Stankoff B, Mrejen S, Tourbah A, Fontaine B, Lyon-Caen O, Lubetzki C, Rosenheim M: Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology 2007;68:779–781.
24.
Worthington J, Jones R, Crawford M, Forti A: Pregnancy and multiple sclerosis: a 3-year prospective study. J Neurol 1994;241:228–233.
25.
Shehata HA, Okosun H: Neurological disorders in pregnancy. Curr Opin Obstet Gynecol 2004;16:117.
26.
Bennett A: Pregnancy and multiple sclerosis. Clin Obstet Gynecol 2005;48:38–47.
27.
Airas L, Saraste M, Rinta S, et al: Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 2008;151:235–243.
28.
Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004;127:1917–1927.
29.
Van Walderveen MA, Tas MW, Barkhof F, et al: Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis. Neurology 1994;44:327–329.
30.
Keith AB: Effect of pregnancy on experimental allergic encephalomyelitis in guinea pigs and rats. J Neurol Sci 1978;38:317–326.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.